Related Experiment Videos
Genetically modified filamentous phage as bactericidal agents: a pilot study
1Department of Microbiology and Genetics, Max F. Perutz Laboratories, University Departments at the Vienna Biocenter, Vienna, Austria.
Letters in Applied Microbiology
|September 13, 2003
Summary
Genetically engineered phages efficiently kill bacteria without cell lysis, minimizing endotoxin release. This offers a safer strategy for using bacteriophage therapy against infections.
Area of Science:
- Microbiology
- Molecular Biology
- Biotechnology
Background:
- Bacteriophage therapy is a promising alternative to antibiotics.
- Conventional lytic phages cause host cell lysis, releasing endotoxins.
- Controlling endotoxin release is crucial for safe phage applications.
Purpose of the Study:
- To assess the efficacy of engineered filamentous phages in killing bacteria.
- To determine if engineered phages can prevent host-cell lysis.
- To evaluate endotoxin release compared to lytic phages.
Main Methods:
- Engineered M13 phage expressing lethal proteins (BglII or lambda S holin) were used.
- Infection of growing Escherichia coli cultures.
- Bacterial survival and endotoxin levels were quantified.
Main Results:
- Engineered phages demonstrated high bacterial killing efficiency.
- Infected bacterial cells remained structurally intact.
- Significantly reduced endotoxin release compared to lytic phage infection.
Conclusions:
- Genetically engineered phages can effectively kill bacteria without lysis.
- This approach minimizes pyrogenic cell wall component release.
- Engineered phages represent a viable strategy for safer bactericidal applications.